Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
Johnson & Johnson(JNJ) stock is priced at $204.43, giving the company a market capitalization of 492.53B. It carries a P/E multiple of 19.46 and pays a dividend yield of 2.5%.
On 2025-12-10, Johnson & Johnson(JNJ) stock moved within a range of $200.00 to $204.69. With shares now at $204.43, the stock is trading +2.2% above its intraday low and -0.1% below the session's peak.
Trading volume for Johnson & Johnson(JNJ) stock has reached 2.6M, versus its average volume of 8M.
The stock's 52-week range extends from a low of $140.68 to a high of $207.81.
The stock's 52-week range extends from a low of $140.68 to a high of $207.81.
JNJ News
Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor mod...
Johnson & Johnson JNJ and Pfizer PFE are both healthcare leaders with large drug portfolios and diversified revenue streams, making them direct peers in the blu...
HSBC raised the firm’s price target on Johnson & Johnson to $240 from $215 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group....
Analyst ratings
59%
of 27 ratingsMore JNJ News
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Johnson & Johnson yesterday and set a price target of $190.00. TipRanks Cyber Monday Sale Claim...
In early trading on Tuesday, shares of Johnson & Johnson topped the list of the day's best performing Dow Jones Industrial Average components, trading up 1.4%....
Johnson & Johnson announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI plus DARZALEX FASPRO as early...
Johnson & Johnson (JNJ) keeps grinding higher, and with the stock up roughly 14% over the past 3 months and nearly 40% year to date, investors are asking what i...
Why 2026 Could Be the Breakout Year for Dividend Growth Investors Quick Read Procter & Gamble (PG) has raised dividends for 69 consecutive years with a current...
Johnson & Johnson JNJ faces several challenges, like potential losses from expiring drug patents, ongoing legal battles related to its talc powder and broader m...
Eli Lilly (LLY), Pfizer (PFE), and Johnson & Johnson (JNJ) have secured spots on China’s drug catalog, with a total of 19 medicines making the list, Amber Tong...